Sorafenib reduces proliferation of glioblastoma cultures, and this effect depends, at least in part, on the inhibition of PI3K/Akt and MAPK pathways.Sorafenib significantly induces apoptosis/cell death via downregulation of the survival factor Mcl-1.Sorafenib has a selective action on glioblastoma stem cells. Here, MCL1 is linked to glioblastoma.